ATE332708T1 - Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält - Google Patents
Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthältInfo
- Publication number
- ATE332708T1 ATE332708T1 AT01941917T AT01941917T ATE332708T1 AT E332708 T1 ATE332708 T1 AT E332708T1 AT 01941917 T AT01941917 T AT 01941917T AT 01941917 T AT01941917 T AT 01941917T AT E332708 T1 ATE332708 T1 AT E332708T1
- Authority
- AT
- Austria
- Prior art keywords
- pde4 inhibitor
- cancer treatment
- composition containing
- treatment composition
- antineoplastic agent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010065553 Bone marrow failure Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028116 Mucosal inflammation Diseases 0.000 abstract 1
- 201000010927 Mucositis Diseases 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20984600P | 2000-06-06 | 2000-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE332708T1 true ATE332708T1 (de) | 2006-08-15 |
Family
ID=22780552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01941917T ATE332708T1 (de) | 2000-06-06 | 2001-06-04 | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1289557B1 (de) |
| JP (1) | JP2003535148A (de) |
| AT (1) | ATE332708T1 (de) |
| AU (1) | AU2001275228A1 (de) |
| DE (1) | DE60121440T2 (de) |
| ES (1) | ES2267778T3 (de) |
| WO (1) | WO2001093909A2 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005014A (es) | 2000-12-06 | 2004-09-10 | Robert J Hariri | Metodo para recolectar celulas madres de la placenta. |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| AU2002251935B2 (en) | 2001-02-14 | 2007-11-29 | Celularity Inc. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| EP2338983B1 (de) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Regeneration und Repopulation von dezellularisierten Geweben und Kadaverorganen durch Stammzellen. |
| WO2002094321A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
| KR20040007583A (ko) * | 2001-05-23 | 2004-01-24 | 다나베 세이야꾸 가부시키가이샤 | 연골 질환의 재생치료용 조성물 |
| PT1908463E (pt) * | 2001-12-14 | 2011-12-19 | Merck Serono Sa | Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico |
| CA2481385A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| AU2003298775B2 (en) | 2002-11-26 | 2008-07-17 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| US7470538B2 (en) | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| PL378247A1 (pl) * | 2003-01-14 | 2006-03-20 | Altana Pharma Ag | Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| EP1957633B1 (de) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunmodulation unter verwendung von plazentastammzellen |
| AU2006332679A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| KR20180105266A (ko) | 2005-12-29 | 2018-09-27 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
| CN103356710A (zh) | 2007-02-12 | 2013-10-23 | 人类起源公司 | 利用胎盘干细胞治疗炎性疾病 |
| US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| EP2203176B1 (de) | 2007-09-28 | 2014-11-26 | Anthrogenesis Corporation | Tumorsuppression mit menschlichem plazentaperfusat und menschlichen natürlichen killerzellen eines zwischenproduktes aus der plazenta |
| NZ591292A (en) | 2008-08-20 | 2012-10-26 | Anthrogenesis Corp | Improved cell composition and methods of making the same |
| WO2010059828A1 (en) | 2008-11-19 | 2010-05-27 | Anthrogenesis Corporation | Amnion derived adherent cells |
| CA2787992A1 (en) | 2010-01-26 | 2011-08-04 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
| PL2556145T3 (pl) | 2010-04-07 | 2017-02-28 | Anthrogenesis Corporation | Angiogeneza z zastosowaniem łożyskowych komórek macierzystych |
| MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| DK2714059T3 (en) | 2011-06-01 | 2019-01-21 | Celularity Inc | TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS |
| US20150157584A1 (en) * | 2012-06-11 | 2015-06-11 | The J. David Gladstone Institutes | Inhibitors of hippo-yap signaling pathway |
| EP3622960A1 (de) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natürliche killerzellen aus plazenta |
| US11052101B2 (en) | 2019-03-25 | 2021-07-06 | National Guard Health Affairs | Methods for treating cancer using purine analogs by depleting intracellular ATP |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK122199A3 (en) * | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| JP2002500188A (ja) * | 1998-01-08 | 2002-01-08 | ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション | A2aアデノシンレセプター作動因子 |
| EP1067919A1 (de) * | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo und sulindac in krebs-präventiven kombinationen |
| AU6047099A (en) * | 1998-09-24 | 2000-04-10 | Boston Medical Center Corporation | Compositions and methods for the treatment of chronic lymphocytic leukemia |
| EP1278519A4 (de) * | 2000-04-12 | 2003-05-07 | Cell Pathways Inc | Behandlungsmethode eines patienten mit neoplasie durch behandlung mit einem topoisomerase i inhibitor |
| EP1188438A1 (de) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen |
-
2001
- 2001-06-04 EP EP01941917A patent/EP1289557B1/de not_active Expired - Lifetime
- 2001-06-04 AT AT01941917T patent/ATE332708T1/de not_active IP Right Cessation
- 2001-06-04 JP JP2002501480A patent/JP2003535148A/ja active Pending
- 2001-06-04 WO PCT/US2001/018108 patent/WO2001093909A2/en not_active Ceased
- 2001-06-04 ES ES01941917T patent/ES2267778T3/es not_active Expired - Lifetime
- 2001-06-04 AU AU2001275228A patent/AU2001275228A1/en not_active Abandoned
- 2001-06-04 DE DE60121440T patent/DE60121440T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2267778T3 (es) | 2007-03-16 |
| EP1289557B1 (de) | 2006-07-12 |
| JP2003535148A (ja) | 2003-11-25 |
| WO2001093909A2 (en) | 2001-12-13 |
| AU2001275228A1 (en) | 2001-12-17 |
| DE60121440T2 (de) | 2007-06-28 |
| EP1289557A2 (de) | 2003-03-12 |
| DE60121440D1 (de) | 2006-08-24 |
| WO2001093909A3 (en) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121440D1 (de) | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält | |
| IL165267A (en) | A drug comprising a mixture of an amino phospholipid antibody and a selected antiviral agent or antiviral vaccine conjugate, and an amino phospholipid binding antibody for use in the treatment or prevention of viral infections or diseases | |
| CR7693A (es) | Terapia de combinacion para enfermedades hiperproliferativas | |
| NO20024610D0 (no) | Synergistiske metoder og blandinger for behandling av kreft | |
| WO2002056912A3 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
| BRPI0006634B8 (pt) | composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios | |
| WO2002072031A3 (en) | Substituted tetracycline compounds as synergistic antifungal agents | |
| PT932402E (pt) | Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| WO2001051043A3 (en) | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols | |
| NO20034204L (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
| BR9709942A (pt) | Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo | |
| NO20041598L (no) | Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er) | |
| DE60216300D1 (de) | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption | |
| DE69940951D1 (de) | Nd wachstumshemmende mittel | |
| ES2192832T3 (es) | Uso de compuestos macrolidos para tratar glaucoma. | |
| PT1109571E (pt) | Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos | |
| WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
| TR199901104T2 (xx) | Farmas�tik bile�ikler. | |
| TR200401669T1 (tr) | Neoplastik hastalıkların tedavisi için metarix-metalloproteinazları önleyen kompozisyon. | |
| BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
| BR9808221A (pt) | Método de tratamento de tumor. | |
| WO2003013554A3 (en) | Aromatase inhibitors from broussonetia papyrifera | |
| WO2002062334A3 (en) | Cancer chemopreventative compounds and compositions and methods of treating cancers | |
| WO2002041831A3 (en) | Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |